Therefore, we measured the frequency of EGFR T790M in an EGFR-mutant lung cancer cell line resistant to EGFR-TKIs, which were established using two different drug-treatment regimens, in order to determine the relevance of these regimens to the emergence of clinically relevant drug resistance. This evidence concerns the gene EGFR and lung carcinoma.